Hospital-adapted inhaled phage cocktail as a component of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections

Study objective To evaluate the feasibility, safety, and potential stewardship benefits of adding a hospital-adapted inhaled bacteriophage cocktail to antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections. Materials and methods This prospective, single-center, post hoc secondary analysis of data from a prospectively conducted randomized controlled trial, restricted to participants receiving systemic antibiotic therapy at baseline, included 96 chronically critically ill patients with lower respiratory tract infections. Fifty-six patients received antimicrobial therapy plus an inhaled hospital-adapted phage cocktail, and 40 received antimicrobial therapy alone. The phage cocktail was nebulized three times a day for 21 days. Results The use of an inhaled bacteriophage cocktail as part of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections demonstrated a clinical safety profile. Adjunctive inhaled phage therapy was not associated with clinically apparent treatment-limiting adverse events during the 21-day follow-up; between-group differences in ALT, AST, bilirubin, and creatinine were not statistically significant on day 21. Baseline-adjusted analyses did not identify statistically significant between-group differences in CRP, chest CT score, or BAL culture score at day 21, although adjusted point estimates for chest CT and BAL culture scores were in the direction of lower scores in the intervention group. Conclusions Adjunctive inhaled phage therapy was feasible, and no treatment-limiting adverse events were reported during the 21-day follow-up. A lower cumulative frequency of escalation to Reserve antibiotics was observed on day 14. These findings support further evaluation in a multicenter randomized trial.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fmed.2026.1974589
Primary Topic
Bacteriophages and microbial interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hospital-adapted inhaled phage cocktail as a component of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections

Зурабов Федор Михайлович, Marina M. Gurkova, Andrey V. Grechko, Кузовлев Артем et al.
Frontiers in Medicine
Bacteriophages and microbial interactions
article

Hospital-adapted inhaled phage cocktail as a component of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections

Зурабов Федор Михайлович, Marina M. Gurkova, Andrey V. Grechko, Кузовлев Артем, Viktoria Uskevich, Yakovlev Alexey, Tatyana Kochetova, Ekaterina Chernevskaya, Mikhail Yuryev, Alexander Zurabov, Petr Polyakov, Marina Petrova
article en

Abstract

Study objective To evaluate the feasibility, safety, and potential stewardship benefits of adding a hospital-adapted inhaled bacteriophage cocktail to antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections. Materials and methods This prospective, single-center, post hoc secondary analysis of data from a prospectively conducted randomized controlled trial, restricted to participants receiving systemic antibiotic therapy at baseline, included 96 chronically critically ill patients with lower respiratory tract infections. Fifty-six patients received antimicrobial therapy plus an inhaled hospital-adapted phage cocktail, and 40 received antimicrobial therapy alone. The phage cocktail was nebulized three times a day for 21 days. Results The use of an inhaled bacteriophage cocktail as part of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections demonstrated a clinical safety profile. Adjunctive inhaled phage therapy was not associated with clinically apparent treatment-limiting adverse events during the 21-day follow-up; between-group differences in ALT, AST, bilirubin, and creatinine were not statistically significant on day 21. Baseline-adjusted analyses did not identify statistically significant between-group differences in CRP, chest CT score, or BAL culture score at day 21, although adjusted point estimates for chest CT and BAL culture scores were in the direction of lower scores in the intervention group. Conclusions Adjunctive inhaled phage therapy was feasible, and no treatment-limiting adverse events were reported during the 21-day follow-up. A lower cumulative frequency of escalation to Reserve antibiotics was observed on day 14. These findings support further evaluation in a multicenter randomized trial.

Frontiers in MedicineVol. 13
MicroMir (RU)
Good health and well-being
Bacteriophages and microbial interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon